Drugs / CD5CART
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05596266 | Oct 2022 → Dec 2024 | T-cell acute lymphoblastic leukemia | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT05032599 | Sep 2021 → Sep 2023 | T-cell acute lymphoblastic leukemia | Beijing Boren Hospital | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07234110 | Sep 2025 → May 2027 expected | refractory hematologic cancer | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD5 CAR-T | “Single-center, Single-arm Exploratory Clinical Study on the Safety and Efficacy of Human CD5 Chimeric Antigen Receptor T Cell Injection CD5CART in the Treatment of Relapsed and...” NCT07234110 ↗ |
| Action | Deplete | “CAR-T cells persisted and cleared CD5+ T cells” PMID 39354195 ↗ Oct 2024 |
| Modality | Cell therapy | “CD5-gene-edited CAR-T cell therapy” PMID 39354195 ↗ Oct 2024 |
| Route | Intravenous | “CD5 CAR-T will be administered by I.V. infusion.” NCT05596266 ↗ |
| Target | CD5 | “targeting CD5” PMID 39354195 ↗ Oct 2024 |